Tumor News and Research

RSS

Lilly, Merck announce another immuno-oncology collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types.

10 Dec 2015

Renowned experts, Nobel laureates to convene at Toulouse Onco Week to discuss latest advances in oncology

The first Toulouse Onco Week (TOW) is due to take place from 3 to 6 February 2016 at the Pierre Baudis Congess Center, Toulouse, France. This unique event will be focused on the international fight against cancer by bringing together stakeholders from around the world and presenting the latest global innovations in oncology.

10 Dec 2015

Scientists discover that blocking RANKL protein stops osteosarcoma

Scientists at Princess Margaret Cancer Centre have discovered that blocking the master regulator of bone renewal stops osteosarcoma - the most common primary bone cancer in children and teens, and the malignant disease that was fatal for Canadian icon Terry Fox.

10 Dec 2015

Study reveals pathogenetic role of miR-125a in pulmonary hypertension

Pulmonary hypertension is an umbrella term used for many conditions that all result in elevation of the pulmonary arterial pressure. Of interest, many of these completely different clinical and pathophysiological entities result in a final common pathway of vasoconstriction, micro thrombosis and vascular remodelling.

10 Dec 2015

TET proteins needed to maintain genome instability, say researchers

Members of the TET (short for ten-eleven translocation) family have been known to function as tumor suppressors for many years, but how they keep a lid on the uncontrolled cell proliferation of cancer cells had remained uncertain. Now, researchers at the La Jolla Institute for Allergy and Immunology demonstrate that TET proteins collectively constitute a major class of tumor suppressors and are required to maintain genome instability.

9 Dec 2015

New three-drug delivery system shows promise for treatment of metastatic melanoma

Researchers have developed a new three-drug delivery system for cancer treatment, especially metastatic melanoma, the deadliest form of skin cancer - and shown that the system may have particular value with cancers like this that often spread through the lymphatic system.

9 Dec 2015

Dietary sugar may help to treat melanoma

New research from scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) suggests that a rare sugar found in seaweed, mushrooms, seeds and other foods may be able to help treat skin cancer.

9 Dec 2015

Palbociclib and paclitaxel combination shrinks tumors in patient with ER positive breast cancer

Combining the new breast cancer drug palbociclib with paclitaxel (Taxol) shrank tumors in nearly half of patient with estrogen-receptor (ER) positive breast cancer, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

9 Dec 2015

NeoGenomics introduces NeoLAB Solid Tumor Monitor, NeoLAB BTK Inhibitor Acquired Resistance test

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today an expansion of its liquid biopsy testing menu to include two new tests, a NeoLAB Solid Tumor Monitor and a NeoLAB BTK Inhibitor Acquired Resistance test.

8 Dec 2015

OncoSec reports net loss of $7.0 million for first quarter of fiscal 2016

OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the first quarter of fiscal year ended July 31, 2016.

8 Dec 2015

Scientists reveal why loss of CD73 enzyme in human cancer promotes tumor progression

Scientists have shown for the first time why loss of the enzyme CD73 in human cancer promotes tumor progression.

8 Dec 2015

New Loyola Center for Cancer Care & Research opens at Palos Community Hospital

The new Loyola Center for Cancer Care & Research at Palos Community Hospital is offering cancer patients academic level care close to home.

8 Dec 2015

Researchers discover 'triple attack' technique to target liver cancer tumors

In an interdisciplinary collaboration between prominent academic and industry investigators, researchers have discovered a novel method for repositioning an FDA-approved anti-cancer compound so it can specifically target liver cancer tumors. A 'triple attack' technique combining chemotherapy, thermal ablation, and hyperthermia provided a highly targeted, yet minimally invasive approach.

8 Dec 2015

BioAtla, Pfizer sign license and option agreement for new class of antibody therapeutics

BioAtla LLC, a biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a license and option agreement with Pfizer Inc. to advance the development and commercialization of a new class of antibody therapeutics based on BioAtla's CAB platform and utilizing Pfizer's proprietary antibody drug conjugate (ADC) payloads.

8 Dec 2015

Study: Certain characteristics can lead to therapy-related leukemia in breast cancer survivors

A new analysis indicates that certain characteristics may increase a breast cancer survivor’s risk of developing leukemia after undergoing chemotherapy and/or radiation. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings are a first step toward finding ways to prevent this serious and potentially life-threatening treatment-related complication.

8 Dec 2015

Researchers unveil relationship between ovarian cancer and obesity

Ovarian cancer is a deadly disease, one that's hard to detect until it has progressed significantly. More than 75 percent of women diagnosed with ovarian cancer have metastasis at the time of diagnosis, resulting in a low five-year survival rate of less than 30 percent.

8 Dec 2015

Researchers reveal potential for exploring new treatment options for triple-negative breast cancer

Researchers from Caris Life Sciences and Fox Chase Cancer Center – Temple Health announced the presentation of two studies revealing the potential for exploring new therapeutic options for triple-negative breast cancer (TNBC) at the 2015 San Antonio Breast Cancer Symposium.

7 Dec 2015

Yale study identifies how myeloma cells escape treatment

One of the biggest questions about the treatment of multiple myeloma, a form of blood cancer, is why nearly all patients treated with current therapies eventually suffer relapse. A Yale Cancer Center study may have solved this mystery by identifying how cancer cells escape treatment, leading to recurrence.

7 Dec 2015

EKF biomarker identifies likely development of Diabetic Nephropathy

EKF, announces new data presented in support of soluble Tumour Necrosis Factor Receptor 1 as a biomarker to predict progression of Diabetic Nephropathy.

From EKF Diagnostics 2 Dec 2015

Neoadjuvant chemotherapy can stimulate evolution of breast cancer tumor

Russian scientists have found that neoadjuvant chemotherapy in patients with breast cancer can stimulate evolution of the tumor. The results of the research conducted by Nicholay Litvyakov, D.Sc. at Cancer Research Institute, Head of the Tumor Virology Laboratory, and TSU researcher Marina Ibragimova, were published in "Siberian Journal of Oncology."

1 Dec 2015

Tumor News and Research

Lilly, Merck announce another immuno-oncology collaboration

Renowned experts, Nobel laureates to convene at Toulouse Onco Week to discuss latest advances in oncology

Scientists discover that blocking RANKL protein stops osteosarcoma

Study reveals pathogenetic role of miR-125a in pulmonary hypertension

TET proteins needed to maintain genome instability, say researchers

New three-drug delivery system shows promise for treatment of metastatic melanoma

Dietary sugar may help to treat melanoma

Palbociclib and paclitaxel combination shrinks tumors in patient with ER positive breast cancer

NeoGenomics introduces NeoLAB Solid Tumor Monitor, NeoLAB BTK Inhibitor Acquired Resistance test

OncoSec reports net loss of $7.0 million for first quarter of fiscal 2016

Scientists reveal why loss of CD73 enzyme in human cancer promotes tumor progression

New Loyola Center for Cancer Care & Research opens at Palos Community Hospital

Researchers discover 'triple attack' technique to target liver cancer tumors

BioAtla, Pfizer sign license and option agreement for new class of antibody therapeutics

Study: Certain characteristics can lead to therapy-related leukemia in breast cancer survivors

Researchers unveil relationship between ovarian cancer and obesity

Researchers reveal potential for exploring new treatment options for triple-negative breast cancer

Yale study identifies how myeloma cells escape treatment

EKF biomarker identifies likely development of Diabetic Nephropathy

Neoadjuvant chemotherapy can stimulate evolution of breast cancer tumor

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Exploring the G:Box and for high-quality imaging

Latest News